N-[3-({4-[(3-氨基丙基)氨基]丁基}氨基)丙基]-2-(4-羟基苯基)乙酰胺 | 130210-32-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[3-({4-[(3-氨基丙基)氨基]丁基}氨基)丙基]-2-(4-羟基苯基)乙酰胺
• 英文名称: N-(4-Hydroxyphenylacetyl)spermine
• 英文别名: N-[3-[4-(3-aminopropylamino)butylamino]propyl]-2-(4-hydroxyphenyl)acetamide
• CAS: 130210-32-1
• 化学式: C₁₈H₃₂N₄O₂
• 分子量: 336.5
• InChiKey: DRHUIJOIIKXHEH-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于无菌水

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  99.4
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  对羟基苯乙酸 、 精胺 生成 N-[3-({4-[(3-氨基丙基)氨基]丁基}氨基)丙基]-2-(4-羟基苯基)乙酰胺
  参考文献：
  名称：

  USHERWOOD, PETER NORMAN RUSSELL;BYCROFT, BARRIE WALSHAM;BLAGBROUGH, IAN S+

  摘要：

  DOI：

文献信息

• Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
  申请人：Verheijen C. Jeroen

  公开号：US20050096387A1

  公开（公告）日：2005-05-05

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

  碳酰基酯抑制胆碱酯酶活性，水解后释放出药理活性成分。在一种实施例中，碳酰基酯具有以下结构：其中A选自无取代芳基、取代芳基、无取代杂环芳基和取代杂环芳基的群组。碳酰基酯用于治疗个体的方法中。通过水解碳酰基酯获得的药理活性成分可以治疗例如神经系统疾病、胆碱能缺乏以及与药理活性成分缺乏相关的疾病或病症，例如乙酰胆碱。
• Therapeutic polyamine-amides
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0361687A1

  公开（公告）日：1990-04-04

  A compound of formula I optionally in the form of an acid addition salt in which formula: A represents a substituent which is: hydroxyl, O-alkyl, O-cycloalkyl, O-alkenyl, O-aryl, O-aralkyl, O-carbamate, O-carbonate, O-acyl or halogen a is O-5; the substituents A are identical or different when a is more than 1; B represents a C₁-C₆ aliphatic hydrocarbon group optionally carrying one or more of the substituents: hydroxyl, amino, halogen, C₁-C₄ alkoxy, C₁-C₄ alkyl, aryloxy or carboalkoxy and optionally comprising one or more sites of unsaturatlon and/or one or more carbonyl groups or ketal derivatives thereof; b is O or 1; c, d, f and h, which may be identical or different, are 2, 3, 4, 5 or 6; and i is 0 or 1 D, E and F, which may be identical or different, represent hydrogen or C₁-C₄ alkyl or cycloalkyl, and G and J which may be identical or different represent hydrogen, alkyl or cycloalkyl or G and J together with the nitrogen atom to which they are attached represent a saturated heterocyclic ring system.

  可选择以酸加成盐形式存在的式 I 化合物 式中 A 代表以下取代基 羟基、O-烷基、O-环烷基、O-烯基、O-芳基、O-芳烷基、O-氨基甲酸酯、O-碳酸酯、O-酰基或卤素 a为O-5； 当 a 多于 1 时，取代基 A 相同或不同； B 代表 C₁-C₆ 脂肪族烃基，可选择带有一个或多个取代基： 羟基、氨基、卤素、C₁-C₄ 烷氧基、C₁-C₄ 烷基、芳氧基或羧基烷氧基，并任选包含一个或多个不饱和基和/或一个或 多个羰基或其缩酮衍生物； b 是 O 或 1； c、d、f 和 h（可以相同或不同）为 2、3、4、5 或 6； i 是 0 或 1 D、E 和 F（可以相同或不同）代表氢或 C₁-C₄ 烷基或环烷基，以及 可能相同或不同的 G 和 J 代表氢、烷基或环烷基，或 G 和 J 与它们所连接的氮原子一起代表饱和杂环系统。
• Biocidal polylamine-amides
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0360437A1

  公开（公告）日：1990-03-28

  Compounds of formula I optionally in the form of an acid addition salt in which formula: A represents a substituent which is: hydroxyl, O-alkyl, O-cycloalkyl, O-alkenyl, O-aryl, O-aralkyl, O-carbamate, O-carbonate, O-acyl or halogen a is O-5; the substituents A are identical or different when a is more than 1; B represents a C₁-C₆ aliphatic hydrocarbon group optionally carrying one or more of the substituents: hydroxyl, amino, halogen, C₁-C₄ alkoxy, C₁-C₄ alkyl, aryloxy or carboalkoxy and optionally comprising one or more sites of unsaturation and/or one or more carbonyl groups or ketal derivatives thereof; b is 0 or 1; c, d, f and h, which may be identical or different, are 2, 3, 4, 5 or 6; and i is 0 or 1 D, E and F, which may be identical or different, represent hydrogen or C₁-C₄ alkyl or cycloalkyl, and G and J which may be identical or different represent hydrogen, alkyl or cycloalkyl or G and J together with the nitrogen atom to which they are attached represent a saturated heterocyclic ring system are of value as biocides.

  可选择以酸加成盐形式存在的式 I 化合物 式中 A 代表以下取代基 羟基、O-烷基、O-环烷基、O-烯基、O-芳基、O-芳烷基、O-氨基甲酸酯、O-碳酸酯、O-酰基或卤素 a为O-5； 当 a 多于 1 时，取代基 A 相同或不同； B 代表 C₁-C₆ 脂肪族烃基，可选择带有一个或多个取代基： 羟基、氨基、卤素、C₁-C₄ 烷氧基、C₁-C₄ 烷基、芳氧基或羧基烷氧基，并可选包含一个或多个不饱和位点和/或一个或多个羰基或其缩酮衍生物； b 为 0 或 1； c、d、f 和 h（可以相同或不同）为 2、3、4、5 或 6； i 为 0 或 1 D、E 和 F（可以相同或不同）代表氢或 C₁-C₄ 烷基或环烷基，以及 可能相同或不同的 G 和 J 代表氢、烷基或环烷基，或 G 和 J 与它们所连接的氮原子一起代表饱和杂环环系，具有杀生物剂的价值。
• Methods and compositions for the treatment of alzheimer
  申请人：Universidad del Pais Vasco

  公开号：EP2338492A1

  公开（公告）日：2011-06-29

  The invention relates to AMPA receptor inhibitors and NMDA receptor inhibitors for use in the treatment of a disease associated with deposition of amyloid proteins, more precisely, Alzheimer.

  本发明涉及 AMPA 受体抑制剂和 NMDA 受体抑制剂，用于治疗与淀粉样蛋白沉积有关的疾病，更确切地说，是阿尔茨海默病。
• SUR1 inhibitors for therapy
  申请人：University of Maryland, Baltimore

  公开号：EP2719380A2

  公开（公告）日：2014-04-16

  The present invention provides An NCca-ATP inhibitor for use in a method for treating and/or preventing: (i) colitis or inflammatory bowel disease in an individual; or (ii) subarachnoid hemorrhage or an inflammation related medical condition that is arthritis, eczema, psoriasis, atopic dermatitis, psoriatic arthropathy, asthma, autoimmune diseases, chronic inflammation, chronic prostatitis, glomerulonephritis, hypersensitivities, pelvic inflammatory disease, reperfusion injury, vasculitis, allergies, shoulder tendinitis, myocarditis, nephritis, bursitis or myopathy in an individual.

  本发明提供一种 NCca-ATP 抑制剂，用于治疗和/或预防以下疾病的方法中： (i) 结肠炎或炎症性肠病；或 (ii) 蛛网膜下腔出血或与炎症相关的病症，如关节炎、湿疹、银屑病、特应性皮炎、银屑病关节病、哮喘、自身免疫性疾病、慢性炎症、慢性前列腺炎、肾小球肾炎、过敏性疾病、盆腔炎、再灌注损伤、血管炎、过敏症、肩腱炎、心肌炎、肾炎、滑囊炎或肌病。